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ABSTRACT
Gastrointestinal cancer (GI) is a major health problem. Patients with gastric, 
pancreatic, colorectal, bile duct and gall bladder cancer often have advanced disease 
at the time of diagnosis and are generally difficult to cure, resulting in a dismal 
prognosis for most patients. Inflammation plays an important role in the development 
and growth of cancer, which has led to a growing interest in the pro-inflammatory 
cytokine interleukin 6 (IL-6). 
The aim of the present review was to evaluate the clinical use of IL-6 as a 
biomarker or therapeutic target in patients with GI cancer. We did a systematic review 
of studies (1993–2018), to assess the clinical use of IL-6 as a diagnostic, prognostic 
or predictive tumor biomarker or as a potential therapeutic target. 
This review includes 48 studies and 5316 patients. Circulating IL-6 levels appear 
to be an independent prognostic biomarker in patients with GI cancer, with high IL-6 
levels associated with short overall survival (OS). The results for colorectal cancer 
were too ambiguous to give conclusive results. IL-6 seemed to be a marker for some 
of the clinical characteristics of GI cancer, and may have a role in the diagnostic 
workup in general practice. No published studies have examined the use of IL-6 as a 
therapeutic target in pancreatic, gastric, bile duct or colorectal cancer.
In conclusion, high circulating IL-6 was associated with short OS in most studies 
in GI cancer patients. Whether inhibition of IL-6 would decrease GI cancer symptoms 
and increase quality of life is unknown. 
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 51), pp: 29820-29841
INTRODUCTION
Gastrointestinal (GI) cancer accounted for 
approximately 2.85 million new cases and 1.89 million 
deaths world-wide in 2012 [1]. In this study, we focus on 
gastric cancer, bile duct cancers, pancreatic cancer and 
colorectal cancer. These patients often present with locally 
advanced or metastatic disease at the time of diagnosis, 
and are therefore not candidates for curative surgery [2–7]. 
The prognosis is often dismal, particularly for patients 
with gastric cancer, pancreatic cancer and bile duct cancer, 
which includes cholangiocarcinoma and gallbladder 
cancer. The 5-year overall survival (OS) is only 10–20% 
for gastric cancer [7, 8], 15% for bile duct cancer [9], 
3–7% for pancreatic cancer [5, 6, 10–12], and 50–65% 
for colorectal cancer [3, 13]. In 2015, colorectal cancer 
was the second most common cancer in women, third in 
men, while it is the fourth leading cause of cancer deaths 
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in men and the third in women [3, 14, 15]. Worldwide, 
gastric cancer is the fourth most common cancer and the 
third most common cause of cancer death [1, 15]. Today, 
pancreatic cancer is the seventh most common cause of 
death from cancer [1], and in 2030, pancreatic cancer is 
predicted to become the second leading cause of death 
from cancer [16]. GI cancers are also among the most 
common types of cancer, since colorectal and pancreatic 
cancer both were among the most common cancers in 
2016 together with breast cancer, lung and bronchial 
cancer and prostate cancer [17].
Screening programs for early detection of some 
GI cancers are available in some countries. In Japan 
and South Korea, countries with a very high incidence 
of gastric cancer, national screening programs using 
endoscopy and photofluorography are used to detect 
gastric cancer [8]. However, these screening programs 
are expensive and are only cost-effective in moderate- to 
high-risk populations. A number of non-invasive screening 
techniques are currently being assessed, including gastric-
specific pepsinogen and gastrin-17 [8]. Screening for 
colorectal cancer by feces sampling and colonoscopy is 
used in many countries [18, 19], presumably resulting in 
colorectal cancer being diagnosed 2 to 3 years earlier than 
without screening. However, the screening may result in 
overtreatment, given that most adenomas never develop 
into cancer [2].
New biomarkers for the early detection and 
evaluation of prognosis for patients with GI cancers are 
therefore pivotal [20, 21]. A tumor biomarker indicates 
that a tissue has become malignant or indicates the likely 
behavior of the tumor in terms of prognosis or response to 
therapy [22]. Very few biomarkers are currently used in 
daily clinical practice. Serum levels of carcinoembryonic 
antigen (CEA) are used to follow treatment efficacy in 
patients with gastric and colorectal cancer and to monitor 
gastric and colorectal cancer patients after surgery to 
detect recurrences early [23]. Serum CEA is also used as 
a stage-dependent prognostic biomarker in patients with 
colorectal cancer, but its clinical usage is hampered by a 
low sensitivity [24]. Serum levels of cancer antigen 19.9 
(CA 19.9) are used to follow treatment efficacy in patients 
with pancreatic cancer and colorectal cancer, and after 
surgery to identify recurrences early, but serum CA 19.9 
is neither sufficiently sensitive nor specific [4, 25]. Serum 
CA 19.9 is also a prognostic biomarker and associated 
with disease burden in pancreatic cancer patients, but not 
all patients with pancreatic cancer have elevated levels of 
serum CA 19.9 [5, 26, 27].
Recently the cytokine interleukin-6 (IL-6) has been 
subject to increased attention due to its possible usefulness 
as a biomarker of inflammation. This review aims to 
investigate whether circulating levels of IL-6 can be used 
as a diagnostic or prognostic biomarker in patients with 
GI cancer and to assess its potential as a therapeutic target.
Interleukin-6
IL-6 is a pleiotropic, pro-inflammatory cytokine 
involved in many biological processes, including cancer 
and autoimmune diseases. The protein is a 21–28 kDa 
4-helix bundled glycoprotein consisting of 184 amino acids 
[28–30]. IL-6 is produced by various normal cell types such 
as macrophages, monocytes, stromal cells, hematopoietic 
cells, epithelial cells and muscle cells, playing an important 
role in inflammation, immunity, reproduction, metabolism, 
hematopoiesis, neural development, bone remodeling and 
angiogenesis [31, 32]. In the tumor microenvironment, 
IL-6 is produced by multiple cell types including tumor 
infiltrating immune cells, fibroblast stromal cells and the 
tumor cells themselves, induced by various factors such 
as NF-κB, prostaglandin E2 (PGE2), interleukin-β (IL-
1β), hypoxia, the lack of STAT3-inhibitors such as SOCS, 
microRNAs (miRNA) among others [29–31, 33–35]. IL-6 
is part of a complex mixture of cytokines and chemokines 
in the tumor microenvironment [36]. IL-6 executes its 
function by binding to its receptor (R), either through the 
membrane bound receptor (mIL-6R) called the classical 
pathway, or through the trans-signaling pathway by binding 
to the soluble receptor (sIL-6R) in the tissue [30, 37]. In 
the classical pathway, IL-6 binds the mIL-6R, which is 
largely restricted to a small number of cells (leukocytes, 
megakaryocytes, hepatocytes and certain epithelial 
cells), and is important for the acute-phase response, 
hematopoiesis and homeostatic processes. When binding 
to the mIL-6R, the IL-6-mIL-6R-complex dimerizes, binds 
and activates the trans-cellular gp130. In the trans-signaling 
pathway, IL-6 binds to sIL-6R, the IL-6-sIL-6R-complex 
dimerizes and binds to the trans-cellular gp130, hence 
activating it. The trans-signaling pathway is particularly 
important in inducing the tumor-microenvironment, 
controlling leukocyte recruiting and the activation of tumor-
associated stromal cells. Since gp130 is not restricted to 
specific cell types, the trans-signaling pathway can occur 
in the majority of cells [36]. In both pathways, gp130 is 
activated, which leads to the activation of gp130-associated 
JAKs (JAK1, JAK2, TYK2) to bind to the Box-domains 
in the gp130 protein, leading to a transphosphorylation 
and full activation of JAKs. Downstream, the STAT-
family proteins are now capable of recognizing and 
binding to the docking sites of the activated JAKs, in 
order for JAK to phosphorylate and activate STAT [38]. 
In terms of malignancies, STAT3 is the more important 
member of the STAT-family inducing tumor growth and 
immunosuppression [29]. The activated STAT3 results 
in dimerization of the STAT3, which translocates to the 
nucleus and binds promoter regions of target genes, leading 
to secretion of pro-inflammatory factors and acute-phase 
proteins (e.g. IL-1β, IL-8) and resulting in an anti-apoptotic 
state of the cell inducing cell survival (cyclin D1, MYC, 
Bcl-xL and survivin) [29, 31, 39], angiogenesis (VEGF) 
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and invasion (matrix metalloproteases) [29], and secreting 
immunosuppressive factors (IL-10, TGFβ and VEGF) [28, 
29] increasing chances for completing the cell cycle and cell 
and tumor growth [30, 31, 40–43]. Hence, high IL-6 levels 
promote an anti-apoptotic, proliferative state in tumor cells, 
thereby enabling the tumor cells to become anti-cancer drug 
resistant to both chemotherapy and cancer immunotherapy 
[38, 40, 41]. IL-6 has been shown to play an important role 
in regulating the proliferation and differentiation of T and 
B lymphocytes and natural killer cells [44]. In a recent 
study, MHC class II expression of Th1 cells was blocked 
by IL-6, hampering the secretion of IFN-γ and IL-2, thereby 
reducing the cytotoxic T-lymphocyte activity, enabling 
the cancer cells to evade the anticancer immunological 
reaction [37]. 
Various factors increase such as growth factors in 
the microenvironment (IL-1β, NF-κB, PGE2, low O2) and/
or their active receptors, and the lack of STAT3 inhibitors 
increase the secretion of IL-6 [29]. Recently, a paracrine 
function of miRNA has been discovered, contributing to 
the idea of a positive feedback loop effect in the IL-6/
JAK/STAT-cascade. Dendrite cells derived from colorectal 
tissue has been found to secrete miRNA-21 and -29b, 
inducing the production of IL-6. IL-6 itself induces more 
miRNA-release. MiRNA binds the TLR8 receptor of the 
immune cells, inducing more IL-6 and other cytokines as 
well as increasing invasion of the tumor cells in vitro [36]. 
IL-6 is a major mediator of inflammation, 
and it is important to elucidate that IL-6 is part of a 
complex, interdepending network of cytokines released 
in inflammatory conditions [36]. IL-6 is particularly 
important in chronic inflammatory conditions such 
as rheumatoid arthritis, inflammatory bowel disease, 
Castlemann’s disease, haematopoietic diseases and after 
physical stress such as surgery or chemotherapy. The 
anti-IL-6R antibody Tocilizumab is already approved in 
the treatment of patients with rheumatoid arthritis [45]. 
Increased levels of serum and/or tumor IL-6 are also seen 
in a number of malignant conditions, both haematopoietic 
malignancies and solid tumors including breast, cervical, 
esophageal, head-and-neck, ovarian, prostate, colorectal, 
pancreatic, hepatocellular, gall bladder, non-small-
cell lung cancer and multiple myeloma, reflecting the 
immunological involvement in cancer. Several studies 
have shown IL-6 to be a prognostic indicator of survival 
as well as predictive in response to therapy in many 
types of cancer [29, 46]. A high IL-6 level is generally 
associated with a poorer outcome, particularly regarding 
renal cell, ovarian and prostate cancer, and correlated to 
more severe symptoms in regards to cancer as well as the 
development of anti-cancer drug resistance [12, 30, 39, 
42, 44, 47–50]. 
Inflammation and the development of cancer
Inflammation is often associated with the development 
of cancer, and GI cancers seem to be particularly sensitive 
to inflammation [51, 52]. Inflammation can both initiate 
and accelerate the development of the cancer lesions, giving 
rise to malignant formation. In GI cancers, the activation 
level of STAT3 seems to be of importance with regard to 
increasing tumor size and proliferation in mouse models, and 
IL-6 seems to be the most important activator of the STAT3-
cascade [52, 53]. It is well documented that inflammation is 
related to the development of gastric cancer, an important 
risk factor being the bacterium Helicobacter pylori, even 
though the precise biological mechanism is unknown [21, 
54, 55]. It is believed that Helicobacter pylori changes the 
expression of miRNAs and IL-6, which in turn downregulate 
other important tumor suppressor proteins such as p53 and 
the protein CDX2. In a study by Chung et al. [56], the 
treatment of gastric cancer cells with Helicobacter pylori 
was shown to regulate miRNA, particularly enhancing 
the expression of miR-195 and miR-488, which plays an 
important role in controlling IL-6. Saito et al. [57] showed 
that CDX2 is suppressed by the activation of the IL-6/STAT3 
signal pathway via miR181b in vitro. CDX2 is involved in 
the intestinal cell differentiation in normal cells, and low 
CDX2 in tumor tissue is associated with a poorer cancer-
specific survival. Hence, there is an increasing interest of the 
role of miRNA in the development of GI cancer. According 
to the EPIC-Eurogast study, 93% of patients with non-cardia 
gastric cancers were infected with Helicobacter pylori [58]. 
This bacterium causes a chronic inflammatory state which 
results in increased reactive oxidative stress, atrophy, 
intestinal metaplasia, dysplasia of gastric mucosa cells and 
increased methylation silencing tumor suppressor genes 
[7, 8, 59]. Reflux (Barrett’s esophagus) also predisposes to 
gastric cancer development [7]. 
A close relationship between chronic inflammation 
in the bile duct and cholangiocarcinoma has also been 
suggested. This is seen in primary sclerosing cholangitis, in 
which the risk of developing cholangiocarcinoma is 8–12% 
[4, 60–62]. In pancreatic cancer, inflammation also seems 
to be concurrent with the precursor lesions of pancreatic 
cancer, i.e. pancreatic intraepithelial neoplasia [11, 12, 
63]. Chronic pancreatitis is an established risk-factor for 
pancreatic cancer, and patients suffering from inflammatory 
bowel disease have a 10-fold increased risk of developing 
pancreatic cancer [11, 12]. Inflammatory bowel disease is 
also an important risk factor in colorectal cancer with more 
than 20% developing colorectal cancer within 30 years of 
disease onset if the disease is poorly controlled [14, 64, 65].
Many studies have investigated the association 
between IL-6 and GI cancers, as well as other cancer 
types, resulting in an acknowledgment of a certain effect 
of IL-6 in developing and sustaining the neoplastic cells. 
Gastric cancer cells secrete IL-6, and an increase of IL-6 in 
serum and gastric cancer tissue appears to regulate tumor 
growth and development in an autocrine loop [59, 66–70]. 
Several in vitro cell studies have been performed regarding 
cholangiocarcinoma [43, 60, 62, 71], and all indicate 
that IL-6 has a pivotal effect on the growth and chemo-
resistance of cholangiocarcinoma cells. IL-6 is secreted by 
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cholangiocytes, which suggests that IL-6 is both a paracrine 
and an autocrine growth factor for normal cholangiocytes 
[60, 62, 72]. The increase of IL-6 in both inflamed and 
neoplastic cholangiocytes and the elevated serum IL-6 in 
patients with cholangiocarcinoma indicate that IL-6 is a 
key mediator of bile duct epithelial disorders, by inducing 
proliferation (MAPK pathway) and upregulating epithelial-
to-mesenchymal transition (STAT3) and anti-apoptotic Bcl-
2 molecules in cholangiocytes (Akt-dependent pathway) 
[43, 60, 71]. Anti-IL-6 was shown to increase the sensitivity 
to chemo-therapy [60], and decrease proliferation [62].
Regarding pancreatic cancer, IL-6 protein 
expression in pancreatic cancer cells is significantly 
increased compared to normal pancreatic cells [34, 73, 74]. 
Recently, a murine study has been performed investigating 
the effect of IL-6 receptor blockade on spontaneously 
arising tumors [49]. In combination with chemotherapy, 
IL-6 receptor blockade induced tumor cell apoptosis, 
tumor regression and improved OS. In a study using an 
orthotopic xenograft model with pancreatic cancer cells 
[63], treatment with Tocilizumab (anti-IL-6R) resulted in a 
remarkable decrease in tumor weight and new metastases 
compared to a control group. In a murine study that 
combined anti-IL-6 and anti-programmed death-1-ligand 
in treating pancreatic cancer [75], a decrease in tumor 
weight was observed compared to the control group and 
mice treated with either drug alone, and the OS improved 
by 35% compared to the control group. The authors also 
highlighted the tolerability of the anti-IL-6 drug, as they 
observed no change in body weight. 
Non-colitis-associated colorectal cancer displays 
large numbers of inflammation cells within the solid 
tumor, which causes the production of mutagens (e.g. ROS 
and NO), tissue injury and pro-inflammatory cytokines, 
including IL-6 [64, 76]. IL-6’s activation of STAT3 appears 
to protect the epithelium of the GI tract from apoptosis and 
stimulates regeneration [53, 64, 77], and high IL-6 levels 
have been associated with increased colorectal cancer 
tumor risk [65]. Ying et al. [78] showed that IL-6 plays 
a pivotal role in the development of cancer stem cells in 
colorectal cancer and that anti-IL-6-antibody significantly 
increased chemo sensibility, and Cross-Knorr et al. [13] 
showed that apoptosis of murine colorectal cancer cells 
induced by oxaliplatin was lowered from 32% to 19% 
when colorectal cancer cells were co-treated with IL-6. 
REVIEW CRITERIA
PubMed was searched in September 2016 for 
articles involving IL-6 and GI cancer published in English-
language journals. The search was repeated in April 
2018 to detect recently published studies. The primary 
purpose of the search was to identify clinical studies 
assessing the use of circulating IL-6 as a biomarker or as 
a therapeutic target in patients with GI cancer. The search 
combined these three areas shown in Figure 1, resulting in 
a total of 963 studies. Both medical subject heading and 
free text searching were performed. The articles were 
systematically assessed based on a subjective evaluation 
of the articles’ relevance and categorized into three 
groups: one group, including studies concerning IL-6 
in patients with GI cancer, a second group, containing 
relevant background articles involving both reviews, 
in vitro and in vivo studies of IL-6 and other types of cancer, 
and a third group, containing excluded studies. Articles were 
excluded if IL-6 or cytokine were not mentioned in title or 
abstract and if the study was not based on patients with GI 
cancer, assessing IL-6 as a biomarker or a therapeutic target 
in GI cancer. This was done in two rounds. The first read-
through was primarily based on title. Articles mentioning 
IL-6 and cancer in a diagnostic, prognostic or therapeutic 
context were included either in group one as primary articles 
with results entering this review’s results or in group two as 
supporting articles providing background information. The 
second read-through was based on an abstract or full text 
reading. In case of any doubt of the relevance of an article, 
the article was read thoroughly before deciding its relevance 
for the review. Only 48 articles were included in the results 
of this review, as only English, clinical studies concerning 
the clinical use of IL-6 in gastric cancer, bile duct cancer, 
pancreatic cancer and colorectal cancer were included. 
No murine studies were included in the results, however 
many of these studies are included as supporting articles. 
In addition, the reference lists of the included studies were 
searched for relevant studies.
Another search was done, including only randomized 
controlled trials. This search included all cancer types and 
resulted in 48 studies. Again, the relevance of the article 
was decided based on title and abstract. Furthermore, a 
search was done identifying supporting articles providing 
background information for each of the four cancer types. 
Using the Mesh-word option in PubMed, the search was 
limited to articles concerning humans while covering 
subjects such as anatomy, histology, classification, 
diagnosis, genetics, pathology, prevention and control 
and/or statistics and numerical data. This search included 
only articles that had the relevant cancer types mentioned 
in the title, and the search was narrowed down to include 
only articles published during the past 5 years, resulting 
in 8273 articles regarding gastric cancer, 236 regarding 
bile duct cancer, 7183 regarding pancreatic cancer and 
2261 regarding colorectal cancer. Two of the most recent 
reviews concerning general knowledge of the cancer types 
were included as supporting articles in the review. 
RESULTS
Diagnostic use of circulating IL-6 and 
correlation with clinical characteristics 
34 articles investigated the diagnostic use of 
circulating (i.e. serum or plasma) IL-6 and the correlation 
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Figure 1: Pubmed search. The review was based on six different searches using the search criteria shown in the Figure. The search 
criteria were combined as shown searching PubMed. Search 1 resulted in 963 articles, which were sorted by assessing the relevance of 
the abstract followed by a systematic reading of all non-excluded articles. Search 2 resulted in 48 articles, also sorted by assessing the 
relevance of the abstract followed by a systematic reading of all non-excluded articles. Search 3–6 resulted in a great number of articles. 
Two of the most recent articles were chosen as supporting articles. In the case of doubt of the relevance of a given article, the article was 
read thoroughly before deciding its relevance.
Oncotarget29825www.oncotarget.com
between IL-6 and clinical characteristics. A tumor 
biomarker should be able to accurately detect malignancies 
or predict the behavior of the tumor or response to therapy 
[20, 22]. A diagnostic tumor biomarker is a biomarker used 
in differential diagnostics, which detects malignancy and 
separates the healthy subgroup from all patients with a given 
malignancy. This demands that a diagnostic biomarker must 
have a high sensitivity in order to detect all malignancies 
and a high specificity in order to avoid the false positive 
cases. In analyzing the results of the studies assessed in 
this section, a study was considered to investigate IL-6 as 
a diagnostic biomarker if a ROC-analysis was performed 
presenting either an AUC or sensitivity and specificity for 
increased IL-6 levels. A study was considered to evaluate 
the correlation between IL-6 and clinical characteristics 
in GI cancer if a test was performed for cancer specific 
findings such as lymph node metastases, invasion, distant 
metastases or tumor size. The test was considered positive 
if a p-value < 0.05 was presented.
Gastric cancer
Six out of the 10 studies investigating gastric cancer 
and IL-6 (Table 1), assessed the correlation between 
clinical characteristics in patients with gastric cancer and 
IL-6, all showing a significant correlation. Ashizawa et 
al. [70] found significantly elevated IL-6 levels in gastric 
cancer patients compared to the healthy controls, and 
significantly elevated IL-6 was found in the presence of 
liver metastases, suggesting an association with tumor 
metastases. Ikeguchi et al. [67] found that high serum 
IL-6 correlated with the depth of tumor invasion, but not 
with lymph node metastases, and Kim et al. [79] found 
significant correlation between increased IL-6 and tumor 
size, tumor depth, lymph node metastases and stage. In 
a study by De Vita et al. [44] assessing both gastric and 
colorectal cancer patients as one cohort, IL-6 levels were 
shown to be significantly increased in patients with distant 
metastases and disseminated disease. 
Sanchez-Zauco et al. [21] assessed the diagnostic 
use of IL-6 in gastric cancer and found a high specificity 
(97%), but a low sensitivity (39%). In contrast to this, 
Kim et al. [79] found a high sensitivity (85.7%) and a low 
specificity (50.1%).
Bile duct cancer
Only two studies focused on the correlation between 
clinical characteristics in patients with bile duct cancer 
and IL-6 (Table 2), and both included few patients. Both 
authors argue that high serum IL-6 levels may be useful in 
distinguishing between different neoplasms and between 
benignity and malignancy. Goydos et al. [72] performed 
a 3-year study assessing serum IL-6 in patients with bile 
duct cancer, and found that serum IL-6 was significantly 
higher in cholangiocarcinoma compared to patients with 
hepatocellular carcinoma, metastatic colorectal cancer 
and benign bile disease. A cut-off serum-IL-6 level above 
100 pg/ml identified 80% of the bile duct cancer patients 
and excluded healthy adults, all patients with benign bile 
disease and 92% of the hepatocellular carcinoma patients. 
Cheon et al. [80] assessed the usefulness of serum IL-6 
in bile duct cancer patients receiving photodynamic 
therapy (14 of the 26 patients), matching pre-therapy and 
post-therapy IL-6 levels to the tumor size. Serum IL-6 
correlated with bile duct cancer tumor mass, which they 
used to define tumor burden, indicating that IL-6 has 
potential as a prognostic biomarker and could be useful in 
assessing the efficiency of treatment. However, Mott and 
Gores [81] commented that tumor mass is not identical to 
tumor burden in bile duct cancer.
Pancreatic cancer
Three studies assessed the use of IL-6 as a diagnostic 
biomarker in patients with pancreatic cancer, all finding 
IL-6 useful (Table 3). Schultz et al. [26] studied a cohort 
of 559 patients and compared the use of serum IL-6 to 
CA 19.9 and found that IL-6 was no better than CA 19.9. 
More pancreatic cancer patients had elevated CA 19.9 
than elevated IL-6. The area under the curve (AUC) for 
the diagnosis of pancreatic cancer was higher for CA 19.9 
(AUC 0.94) compared to IL-6 (AUC 0.87). Both serum 
IL-6 and serum CA 19.9 were associated with tumor stage. 
Mroczko et al. [82] studied the diagnostic applicability 
of IL-6 in differentiating between pancreatic cancer and 
chronic pancreatitis and found that the AUC was higher 
for serum IL-6 (AUC 0.94) than serum CA 19.9 (AUC 
0.86), CEA (AUC 0.89) and CRP (AUC 0.84). 
Colorectal cancer 
Three studies investigated the use of serum IL-6 as 
a diagnostic biomarker in patients with colorectal cancer 
(Table 4). Xu et al. [83] performed a combined study in 
combination with a meta-analysis of prior studies that 
assessed the diagnostic and prognostic value of serum IL-6 
in colorectal cancer. The data indicated that IL-6 might 
be a potential diagnostic biomarker that could be used to 
separate colorectal cancer patients from healthy subjects, 
reporting an AUC of 0.82 in a ROC analysis (95% CI 0.75–
0.89). Using a cut-off level of 2.14 pg/ml, the sensitivity 
was 72% and specificity was 75%. In their meta-analysis, 
AUC was 0.79, sensitivity 72% (95% CI 46%-88%) and 
specificity 74% (95% CI 56%-86%). They concluded that 
due to the heterogeneity of the studies, their results should 
not be considered conclusive. In contrast to this study, 
Zhou et al. [14] preformed a meta-analysis of six published 
studies and found that there was no significant association 
between serum IL-6 levels and the relative risk of colorectal 
cancer. Groblewska et al. [24] demonstrated that IL-6 levels 
were significantly higher in colorectal cancer patients than 
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Table 1: Studies investigating IL-6 and gastric cancer
Gastric cancer
Author Year No. of patients
Diag-
nostic C.C.
Prog-
nostic
Cut-off
(pg/ml) AUC Sens/Spec Survival
Sanchez-Zauco 
et al. [21] 2017 162 + 3.2 0.599
97%
39%
Necula 
et al. [100] 2012 51 + 38 p = 0.022
!
Szczepanik 
et al. [139] 2011 99 + 290 NA
*
Lee et al. [140] 2010 102 + NA
Ikeguchi 
et al. [67] 2009 90 + + 0.8
5y survival:
Low: 70%
High: 48%
p = 0.49
Kim et al. [79] 2009 115 + + − 6.8 86% 50%
3y survival:
Low: 96%
High: 81%
p = 0.01!
Liao et al. [69] 2008 147 + 13
HR = 1.77MV
(1.07–2.92)
p = 0.026
Ashizawa et al. 
[70] 2005 60 + + 2
3y survival:
Low: 87%
High: 43%
p < 0.05
Kai et al. [66] 2005 40 + − 50 NA!
Ilhan et al. 
[123] 2003 42 + NA
!Kaplan Meier curve is presented in the paper. 
*HR only presented for complications. 
C.C. = clinical characteristics, AUC = area under the curve, Sens = sensibility, Spec = specificity.
Table 2: Studies investigating IL-6 and bile duct cancer
Bile duct cancer
Author Year No. of patients
Diag-
nostic C.C.
Prog-
nostic
Cut-off
(pg/ml) AUC Sens/Spec Survival
Yoshitomi et al. 
[101] 2012 25 + NA
HR = 1.123 
(1.008–1.252)
p = 0.035
Cheon et al. 
[80]
2007 14
+ + 2623
73%/92%
58%/100%
Goydos et al. 
[72]
1998 15 + + 100 Sens: 80%
C.C. = clinical characteristics, AUC = area under the curve, Sens = sensibility, Spec = specificity.
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in colorectal adenoma patients and healthy controls, and 
IL-6 levels proved to be a better diagnostic marker (AUC 
0.90) than CEA (AUC 0.79), CRP (AUC 0.82) and CA 19.9 
(AUC 0.65). 
Eighteen studies of patients with colorectal 
cancer [24, 65, 84–99] assessed the correlation between 
circulating IL-6 and clinical characteristics, reporting 
ambiguous results regarding tumor stage, resectability 
of the tumor, lymph node metastases, distant metastases, 
TNM stage and vascular invasion with 11 out of 18 articles 
finding correlation. In many of these studies, only some 
parameters proved significant, and due to the contradicting 
results, IL-6 and its correlation with clinical features 
remain elusive. De Vita et al. [44] assessed both gastric 
and colorectal cancer patients as one cohort, finding IL-6 
levels to be significantly elevated in patients with distant 
metastases and disseminated disease.
Prognostic use of circulating IL-6 
Twenty-seven studies evaluated the prognostic use 
of circulating IL-6. A prognostic tumor biomarker is a test 
that indicates a high or a low risk of a cancer-related event, 
assuming that the patient receives no further treatment, 
if any [22]. A study was considered to investigate the 
prognostic use of IL-6, if the OS was investigated 
presenting either a Kaplan–Meier curve, hazard ratio 
(HR) or median survival times comparing patient groups 
Table 3: Studies investigating IL-6 and pancreatic cancer
Author Year No. of patients
Diag-
nostic C.C.
Prog-
nostic
Cut-off
(pg/ml) AUC Sens/Spec Survival
Kim et al. 
[74] 2016 53 + − 1.6
HR = 1.070 
(0.830–1.378)
p = 0.602
Miura et al.
[135] 2015 79 + 1.2
Tsukinaga et al. 
[105] 2015 7 − 2.0 p = 0.02
*
Arshad et al.
[104] 2013 32 + NA
Low: 7.0 mths
High: 3.1 mths
p = 0.009
Mitsunaga et al. 
[48] 2013 60 + 1.9
HR = 2.10
 (1.19–3.74)MV
p = 0.11
Schultz et al.
[26] 2013 559 + + 4.5 0.87
HR = 2.10 
(1.11–3.60), 
p = 0.011OP
HR = 1.71 
(1.33–2.20), 
p < 0.0001NOP
Nixon et al.
[103] 2012 169 + 18
HR = 2.3 
 (1.7–3.2)
Vizio et al.
[106] 2012 62 + − NA
HR = 1.002
(0.998–1.007)
p = 0.246
Mroczko et al.
[82] 2010 78 + + − 13
0.94
0.84MA NA
Bellone et al.
[102] 2006 41 + NA p = 0.03
!
Okada et al.
[122] 1997 55 + + 3.0
55%
93%
C.C. = clinical characteristics, AUC = area under the curve, Sens = sensibility, Spec = specificity.
MA = meta-analysis, OP = operated, NOP = non-operated.
*No correlation between IL-6 and OS > 1 year and OS < 1 year. Correlation between decrease in IL-6 during treatment and 
better survival.
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Table 4: Studies investigating IL-6 and colorectal cancer
Colorectal cancer
Author Year Nr. ofpatients
Diag-
nostic C.C. Prognostic
Cut-off
(pg/ml) AUC Sens/Spec Survival
Chang et al. 
[65] 2016 164 − − 10 NA
Hara et al. 
[109] 2016 53 + 4.3
3y survival:
Low: 71.4%
High: 21.3%
p = 0.02 
Thomsen et al. 
[107] 2016 393 + 5.6
HR = 1.92 
(1.56–2.37) 
p < 0.001)
Xu et al. [83] 2016 72 + + 2.1 0.820.79MA
72% / 
75%, 72% 
/ 74%
HR = 1.76  
(1.42–2.19)
Olsen et al. [84] 2015 189 − NA
Hazama et al.
[141] 2014 17 + 2.0
HR = 4.21 
(1.29–13.76) 
p = 0.015
Reitter et al. 
[142] 2014 726 + NA
HR = 2.27  
(1.227–4.371) 
p = 0.009
Lee et al. [87] 2013 77 + − 9.1
OR = 0.26 
(0.48–13.70)
p = 0.265
Liu et al. [108] 2013 38 − 3.4
HR = 3.1 
(1.4–6.6)
p = 0.004A
Shimazaki et al. 
[85] 2013 46 + + 2.4
HR = 4.1  
(1.20–13.98) 
p < 0.024
Kantola 
et al. [86] 2012 148 + + NA 0.72
Eldesoky et al. 
[88] 2011 35 + 6.7
Svobodova 
et al. [143] 2011 174 − NA
Kwon et al. [89] 2010 132 − − 12
HR = 1.391  
(0.36–5.44) 
p = 0.634
Yeh et al. [90] 2010 99 − + 10
HR = 0.403 
(0.184–0.881) 
p = 0.023* 
Groblewska 
et al. [24] 2008 76 + + − 13 0.90
OR = 1.005 
p = 0.402
Chung et al. 
[91] 2006 106 + (+)
T 12
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with high and low serum IL-6 levels. To be considered 
positive, the test should result in a p-value < 0.05, a HR 
and confidential interval >1.00.
Gastric cancer
Although the number of studies of patients with 
gastric cancer was small, all studies found a significant 
association between high serum IL-6 and short OS, 
suggesting a prognostic value in gastric cancer (Table 1). 
The most recent study performed by Necula et al. [100] 
showed an association between increased plasma IL-6 and 
tumor progression and between high tissue and plasma 
IL-6 levels and OS. Using a cut-off value of 1.97 pg/ml, 
Ashizawa et al. [70] found that OS was significantly 
longer in the low IL-6 level group than in the high IL-6 
level group for both advanced gastric cancer and patients 
with lymphatic invasion. After 1 year, 69% of the gastric 
cancer patients with high IL-6 levels were alive compared 
to 94% of the gastric cancer patients with low serum IL-
6, and after 3 years, the survival rates were 43% and 
87%, respectively. Using multivariate analysis, Liao et 
al. [69] found a significant relation between high IL-6 
and shorter OS (HR 1.77, 95% CI 1.07‒2.92). The gastric 
cancer patients with stage II/III and high IL-6 levels had 
a median survival of 618 days in contrast to 1418 days in 
patients with stage II/III and low IL-6 levels. Kai et al. 
[66] investigated IL-6 as a prognostic biomarker in 
patients with gastric cancer measuring IL-1β and IL-6, 
and found no significant difference in survival between 
patients with high tissue levels of IL-6 (cut-off level 
50 pg/mg-protein) or IL-1β and low serum levels. Kim 
et al. [79] studied serum IL-6 and CRP in 115 gastric 
cancer patients undergoing gastrectomy, and found 
that high IL-6 was associated to short PFS and OS. In 
multivariate analysis, IL-6 was not related to TTP and 
OS. As expected, serum CRP correlated to IL-6, but CRP 
was not correlated to TTP and OS in univariate analyses. 
Bile duct cancer
Only one study has investigated the prognostic use 
of IL-6 in patients with biliary duct cancer (Table 2). In 
a phase II clinical trial, Yoshitomi et al. [101] found that 
increased IL-6 was associated with shorter OS (univariate 
analysis: HR 1.16, 95% CI 1.06‒1.27; multivariate 
analysis: HR 1.12, 95% CI 1.01‒1.25). 
Pancreatic cancer
Nine studies have assessed the use of IL-6 as a 
prognostic biomarker in patients with pancreatic cancer 
(Table 3). Five studies showed IL-6 to be useful [26, 
48, 102, 104]. Schultz et al. [26] found that high IL-6 
in pancreatic cancer patients was associated with short 
OS, and in multivariate analyses, the HR was 1.71 (95% 
CI 1.33–2.20) for high serum IL-6 and 1.54 (95% CI 
1.06–2.24) for high serum CA 19.9 in patients with locally 
Dymicks-
Piekarska 
et al. [92]
2006 41 − NA
Esfandi 
et al. [93] 2006 50 + NA
 Nikiteas et al. 
[94] 2005 74 − + 8 p < 0.05
!
Chung et al. 
[95] 2004 162 + − 12
HR = 1.053
p = 0.861
Belluco et al. 
[96] 2000 208 + + 10
RR = 1.820
(1.095–3.024) 
p = 0.020
5y survival
Low: 69%
High: 45%
Kinoshita et al. 
[97] 1999 55 + 8.3
Ueda et al. [98] 1994 24 + 3.1
C.C. = clinical characteristics, AUC = area under the curve, Sens = sensibility, Spec = specificity.
MA = meta-analysis, T = only tested for tumor IL-6, A = HR represents a four-marker signature with low IL-6 as part of the 
high-risk group.
!Kaplan-Meier curve presented in the article.
*Tested for improved survival. HR also presented for 5 and 10 year survival, both significant. 
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advanced or metastatic pancreatic cancer. In patients who 
had undergone surgery, the HR was 2.03 (95% CI 1.11–
3.70) for high serum IL-6 and 2.51 (95% CI 1.22–5.15) 
for high CA 19.9 levels. The combination of high CA 
19.9 and high IL-6 identified pancreatic cancer patients 
with a very short median survival of only 7.5 months 
compared to 34.4 months for pancreatic cancer patients 
with normal levels of CA 19.9 and IL-6. Thus, IL-6 
appears to be a better prognostic biomarker than CA 19.9 
in non-operable pancreatic cancer patients, but CA 19.9 
is a better prognostic biomarker for pancreatic cancer 
patients who undergo surgery. Mitsunaga et al. [48] 
assessed the prognostic value of IL-6 and IL-1β in patients 
with pancreatic cancer receiving gemcitabine, and using 
multivariate analysis they found that high IL-6/high IL-1β 
levels were an independent prognostic factor for poor OS 
(HR = 2.10) and short PFS (HR = 2.32). In patients only 
presenting high IL-6 levels, there was an association with 
short PFS (p = 0.013), but not for OS (p = 0.053). In a 
study performed using serum from patients participating 
in a phase II clinical trial assessing the tumor response 
in patients with advanced pancreatic cancer receiving 
gemcitabine and IV omega-3 rich lipid emulsion, Arshad 
et al. [104] showed that low IL-6-levels correlated with 
improved OS, with a median OS of 7 months vs. 3.5 
months for patients with high IL-6 levels. Changes in IL-6 
levels were, however, not useful for monitoring treatment.
Kim et al. [74] assessed the serum IL-6 in patients 
with pancreatic cancer, including only patients with 
no or fewer liver metastases. At the last follow-up, the 
patients were separated into a limited and a progressed 
group (liver metastases), with IL-6 levels proving to be 
significantly higher in the progressed group (2.0 versus 
1.4). However, they found no correlation between high 
serum IL-6 and OS (HR = 1.07, 95% CI 0.83–1.38). In 
a small study by Tsukinaga et al. [105], plasma IL-6 
prior to treatment with chemoimmunotherapy was 
not associated to OS, however the decrease in IL-6 
during treatment was associated with better survival 
(p = 0.02). Mrozcko et al. [82] and Vizio et al. [106] 
did not find that serum IL-6 levels in patients with 
pancreatic cancer correlated with shorter OS using 
multivariate analyses. 
Colorectal cancer
Sixteen studies assessed the use of serum IL-6 as a 
prognostic biomarker in patients with colorectal cancer 
with contradicting results (Table 4). Nine of the studies 
found that serum IL-6 was an independent prognostic 
biomarker of OS. Thomsen et al. [107] measured serum 
IL-6 and CRP in 393 patients with metastatic colorectal 
cancer receiving first line chemotherapy. For patients with 
high serum IL-6, the median PFS was 7.7 months and 
the OS 16.6 months compared to 8.9 months (PFS) and 
26 months (OS) for patients with low serum IL-6. This 
significance remained after adjustment for other prognostic 
biomarkers and clinical characteristics. Xu et al. [83] 
performed a meta-analysis of 10 studies investigating the 
prognostic use of IL-6. They found that the pooled HR was 
1.76 (95% CI 1.42–2.19), indicating that high serum IL-6 
in colorectal cancer patients is a predictor of short OS. No 
significant heterogeneity was reported. In this context, 
Yeh et al. [90] showed promising results, as serum IL-6 
proved to be an independent prognostic factor. Using a cut-
off level of 10 pg/ml, the OS of patients with serum IL-6 
>10 pg/ml was significantly shorter after 3 years (HR 0.40, 
95% CI 0.18–0.88), 5 years (HR 0.37, 95% CI 0.20–0.70) 
and 10 years (HR 0.42, 95% CI 0.25–0.73). 
The following studies demonstrated no correlation 
between increased serum IL-6 and OS in patients with 
colorectal cancer. Many of these studies were large, with 
a total of 649 patients as compared to 1794 patients in the 
positive studies. Chang et al. [65] measured serum IL-6, 
IL-1β, TNF-α and CRP, and used median levels of each 
cytokine as cut-off level (10 pg/ml, 10 pg/ml, 55 pg/ml 
and 5 mg/l, respectively). Assessing only PFS, they found 
a tendency to longer PFS in patients with increased serum 
IL-6, but multivariate analysis showed that only tumor 
stage was an independent marker of PFS. High serum 
levels of CRP were associated to a high cytokine intensity 
of IL-1β, TNF-α and IL-6, but no correlation between CRP 
and IL-6 was found. Liu et al. [108] did not find IL-6 to be 
an independent prognostic factor; however, they did find 
that it correlated with outcome in combination with three 
other biomarkers (Ang-2, IGFBP-3 and VCAM-1). 
Meta-analysis of the prognostic use of IL-6 in 
pancreatic and colorectal cancer 
In order to clarify the prognostic value of IL-6 in 
pancreatic cancer and colorectal cancer, we undertook 
a meta-analysis of the two cancer types, see Figure 2. 
Several studies assessed the relationship between IL-
6, pancreatic cancer and colorectal cancer. However, 
the studies included in this meta-analysis are limited 
to studies presenting data with HRs and confidence 
intervals, thereby narrowing the number of articles 
included. It should be noticed that different cut-off levels 
for high and low levels of circulating IL-6 were used 
in the studies included in meta-analysis. Furthermore, 
different follow-up periods and ELISA measurement to 
determine circulating IL-6 levels were used, resulting in 
a significant heterogeneity between the studies in terms 
of both different methodologies and clinical approaches. 
In conclusion, five studies were included in the meta-
analysis concerning pancreatic cancer, representing 817 
patients. The pooled HR for pancreatic cancer was 1.55 
(95% CI 1.11‒2.18). Seven studies were included in the 
meta-analysis concerning colorectal cancer, representing 
1,643 patients. The pooled HR for colorectal cancer was 
2.01 (95% CI 1.69‒2.39). 
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Predictive use of circulating IL-6
A predictive biomarker is a biomarker which 
estimates the relative likelihood that a cancer will 
respond to a specific treatment prior to treatment [22]. 
In investigating a biomarker, a study should include a 
homogenous group of patients randomized to receive 
either standard treatment or the specific treatment assessed 
in the study. The pre-treatment biomarker should foresee 
which patients respond to the treatment by comparing 
OS, PFS or response rate. In this review, a study was 
considered to investigate the predictive use of circulating 
Figure 2: The meta-analysis was performed on selected studies concerning colorectal cancer and pancreatic cancer. op 
= operated patient cohort, n.op = non-operated patient cohort.
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IL-6, if the study assessed how the circulating IL-6 levels 
could identify the group benefitting from treatment in 
two homogenous groups of GI cancer patients receiving 
different treatments. No studies were performed in patients 
with gastric cancer, biliary duct cancer or pancreatic 
cancer. Only one study by Hara et al. [109] assessed the 
predictive use of serum IL-6 in colorectal cancer (Table 4), 
showing IL-6 to be useful as a predictive biomarker. 
They assessed the effect of IL-6 on outcome and 
the response to therapy in patients with advanced or 
metastatic colorectal cancer treated with chemotherapy 
or chemotherapy and bevacizumab combined. High IL-6 
was associated with short PFS in multivariate analysis (RR 
2.1, 95% CI 1.3–3.6). Using the cut-off value 4.3 pg/ml, 
patients with high IL-6 had significantly shorter 3-year 
OS than those with low IL-6 levels (21% vs. 71%). The 
patients with highest IL-6 levels also had significantly 
shorter median PFS (HR = 2.6, 95% CI 1.5–4.8). 
DISCUSSION
Hayes [22] highlights that a tumor biomarker test 
should be used in clinical care only when there is analytic 
validity, clinical validity and clinical utility, meaning 
that the measurement should be accurate and reliable 
and identify a defined disorder or separate a population 
into groups with distinct clinical outcomes. In addition, 
the use of the test results should improve measurable 
clinical outcomes [110]. It has, however, been difficult 
to achieve a satisfying level of evidence due to a lack of 
adequate funding, inappropriately designed studies, non-
publication bias and lack of guidelines when approving 
new biomarkers [111]. Many initiatives have been taken 
to overcome these difficulties. The REMARK (reporting 
recommendation for tumor biomarker prognostic studies) 
guidelines attempt to increase the transparency in 
information provided by studies investigating possible 
tumor biomarkers [111]. The REMARK criteria consist of 
20 items to report, including research goals, hypotheses, 
patient characteristics, assay and measurement methods, 
statistical design and study results [112]. Furthermore, it 
has been suggested that due to the low level of evidence 
most tumor biomarker studies achieve, multiple studies 
must be done to validate the usefulness of a tumor 
biomarker [111]. 
In this review, we assessed the diagnostic and 
prognostic value of circulating IL-6 in patients with GI 
cancer. Many patients with GI cancer have elevated IL-6 
levels, but only a few studies have taken into consideration 
that IL-6 is increased in serum or plasma in patients with 
other types of cancer and other diseases characterized by 
inflammation. IL-6 is part of the systemic inflammatory 
condition following cancer and since IL-6 is produced 
both by cancer cells and inflammatory cells, circulating 
IL-6 may be a biomarker for both inflammation and tissue 
remodeling, and an increase in serum IL-6 is also found 
during acute or chronic stress (e.g. surgical procedures, 
sepsis, inflammatory bowel disease, trauma), and many 
other cancer types, e.g. hepatocecullar carcinoma [25, 72], 
lung [113] breast [114], cervical [115], oesophageal [116], 
head and neck [117, 118], ovarian [119], prostate [120], 
renal cancer [121] and hematological diseases [72]. Hence, 
IL-6 is not cancer specific for a single type of cancer. 
Regarding the results of this review, some studies 
find equivocal results when investigating tumor depth 
invasion or lymph node metastases, but the overall picture 
seems to indicate that high levels of IL-6 are associated 
with severe clinical features of patients with GI cancer. 
The majority of the studies found a difference in serum 
IL-6 between patients with GI cancer and healthy subjects, 
although only few studies investigated the diagnostic use 
of IL-6 properly. Given that IL-6 is not cancer specific, 
the use of IL-6 as a diagnostic biomarker is challenging. 
A biomarker test is used to identify abnormalities in 
patients, and the biomarker should reflect the presence 
of the abnormality [22]. The use of IL-6 as a diagnostic 
tumor biomarker demands close attention to the cut-off 
level. A good diagnostic tumor biomarker detects all 
patients with a given malignancy (high sensitivity) and 
rules out all healthy subjects (high specificity). Hence, 
the cut-off level of IL-6 as a tumor biomarker must be 
sufficiently high in order to only diagnose the patients 
with malignancies and not patient with inflammatory 
conditions, and still relatively low in order to detect all 
patients with malignancies. In the studies assessed in this 
review, sensitivity and specificity were not convincingly 
high, nor superior to other diagnostic methods such 
as serum CEA and CA 19-9, and many cancers would 
not be detected with IL-6 as the diagnostic biomarker. 
Although the use of IL-6 as an independent diagnostic 
tumor biomarker seems doubtful, it may be useful as a 
quick biomarker test in general practice. Patients with 
GI cancers are often diagnosed at advanced stages due to 
unspecific symptoms. High serum IL-6 levels in a subject 
with weight loss and fatigue, but without any signs of 
infections or inflammatory disease, would suggest a need 
for a CT-scan, since the risk of cancer is high if serum IL-6 
is very high. This has to be studied in future studies of 
patients referred to hospital in suspicion of cancer.
The results of the studies investigating IL-6 as a 
prognostic biomarker in patients with GI cancer, require 
a differentiation between the four GI cancers. The studies 
of patients with gastric cancer and biliary duct cancer 
were few and included too few patients to be conclusive. 
Several of the studies with pancreatic cancer and colorectal 
cancer tested a large number of patients and found a 
significant association between high circulating IL-6 
levels and short OS. The studies concerning colorectal 
cancer were however ambiguous. Since the colorectal 
cancer studies involved a large number of patients 
showing different results, the results regarding colorectal 
cancer and IL-6 seems inconclusive. The results of the 
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meta-analysis do, however, show IL-6 to be significant as 
a prognostic biomarker for OS in colorectal cancer. For 
pancreatic cancer, the results of the studies assessed were 
unanimous showing a significant association between 
high circulating IL-6 and short OS, which was confirmed 
in the meta-analysis. This suggests that IL-6 could be a 
useful prognostic biomarker for patients with pancreatic 
cancer. However, several of these studies showed that 
IL-6 had a prognostic value similar to that of the routine 
biomarkers serum CA 19-9 and CEA, so the use of IL-6 
to provide independent information regarding prognosis 
is still unknown. 
It would be interesting to investigate the potential 
role of IL-6 as a prognostic biomarker for both early (stage 
I and II) and late (stage III and IV) GI cancer. This has, 
however, not been possible with the current available 
studies, since only few studies differentiated between 
patients presenting early and late cancer stages. It is 
interesting that Schultz et al. [26] found that IL-6 appears 
to be a better prognostic biomarker than CA 19.9 in non-
operable pancreatic cancer patients, but CA 19.9 is a better 
prognostic biomarker for pancreatic cancer patients who 
undergo surgery. For gastric cancer, Liao et al. [69] found 
IL-6 to be prognostic for stage III and IV, but not for stage 
I and II, and for colorectal cancer, Shimazaki et al. [85] 
found a significant difference in IL-6 levels between stage 
0-II and stage III-IV. Also, we observed a common trend 
showing a significant correlation between median serum 
IL-6 and increasing cancer stages [21, 24, 26, 67, 74, 79, 
82, 88, 91, 93, 95, 96, 98, 102, 106, 122, 123], which 
indicate that IL-6 may be a marker for a more severe type 
of cancer. Future studies should therefor differentiate 
between early and late cancer stages when investigating 
the use of IL-6 as a prognostic biomarker.
Performing a systematic review regarding 
circulating IL-6 in patients with GI cancer in which 
data from multiple studies are evaluated and compared 
provides us with a higher level of evidence. Comparing 
the data has, however, proved to be a challenge. More than 
200.000 articles has been published regarding gastric-, 
pancreatic-, bile duct- and colorectal cancer, however it 
is interesting that only 48 articles assessed the clinical 
use of IL-6 as a biomarker. The limited amount of data 
on IL-6 and GI cancer combined with the fact that the 
studies did not publish all data and the discrepancy in 
what data is considered important to include in the articles, 
have resulted in a hampered comparison of the data. 
Furthermore, studies using different cut-off values of IL-6, 
focusing on multiple end-points, not reporting negative 
results and failure to follow the REMARK criteria 
proposed results that fell short of the desired transparency 
needed to make a systematic review with a high level of 
evidence. In the future, studies dealing with biomarkers 
should follow international reporting guidelines such as 
the REMARK criteria to increase the level of evidence and 
ease the comparison of results.
The role of the inflammatory response in cancer has 
become more appreciated during the past few years [50]. 
Today, tumor-promoting inflammation is seen as an 
enabling mechanism that plays a role in many of the 
hallmarks of cancer, thereby promoting the growth of cancer 
[51]. The inflammatory cells, particularly macrophages 
[42], enhance tumor growth by secreting important growth 
factors into the tissue surrounding the tumor, stimulating 
angiogenesis, invasion, proliferation and cell survival, 
putting the tumor cell in an anti-apoptotic, expansive 
and proliferative state, all of which affects therapeutic 
resistance and a poorer prognosis [50, 51, 124]. Since 
immune cell infiltration can be both tumor-promoting and 
tumor-suppressing, total elimination of the inflammatory 
response is not desirable, and modern medicine must learn 
to influence the tumor microenvironment in order to attract 
and differentiate the immune infiltrate that will produce a 
tumor-suppressing environment [125]. Myeloid cells show 
a great deal of plasticity, being very sensitive to signaling 
compounds surrounding them, and therefore, by blocking 
some of these tumor-promoting signals – for example IL-6, 
which alters this steady-state – the tumor-microenvironment 
can be directed into exerting an anti-tumor action [125]. 
IL-6 has been shown to inhibit the tumor suppressing 
immune cells in colorectal cancer cells by down-regulating 
the activity of cytotoxic T-lymphocytes through suppression 
of the maturation of dendrite cells [37]. In IL-6 deficient 
mice injected with colon cancer cells, tumor growth was 
decreased and dendrite cells, helper T cells and cytotoxic 
T-cells were increased in the tumor microenvironment 
[126]. IL-6 is part of the inflammatory response in many 
types of cancer, but since it is only a small piece of a 
very complex interaction between multiple inflammation 
mediators and a large number of different cells, foreseeing 
the outcome of treating cancer patients with anti-IL-6 
therapeutics is difficult [30, 36]. 
Investigations of the use of IL-6 as a therapeutic 
target in patients with GI cancer have not yet been 
performed. However, IL-6 has been shown to have a 
proliferative effect on gastric cancer cells [68], and it is 
also an important growth factor for neoplastic biliary duct 
cancer [60, 62]. Inhibition of the activation of STAT3, e.g. 
by the anti-IL6R monoclonal antibody Tocilizumab, is 
known to down-regulate the immune suppression caused 
by tumor cells [41], and inhibition of IL-6 signaling may 
be a therapeutic for patients with cancer when IL-6 is over-
expressed [28]. Tocilizumab has been used since 2010 for 
treatment of patients with severe rheumatoid arthritis [45]. 
However, in small clinical trials regarding cancer, treatment 
with anti-IL6 or anti-IL6R has shown no clinical effect in 
patients multiple myeloma [127, 128], metastatic renal 
cell cancer [129] and castration-resistant prostate cancer 
[47]. In patients with recurrent epithelial ovarian cancer, 
a phase I clinical trial recently showed an acceptable 
safety profile and a possible immunological benefit when 
they were treated with Tocilizumab in combination with 
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chemo-therapy [41]. A phase II study is now ongoing, 
testing Tocilizumab in combination with chemo-therapy 
in patients with endothelial ovarian cancer [130], and a 
phase II study is ongoing evaluating whether gemcitabine/
nab-paclitaxel combined with Tocilizumab is more 
effective than gemcitabine/nab-paclitaxel alone in patients 
with locally advanced or metastatic pancreatic cancer 
with elevated serum CRP [130]. So far, treatment with 
Tocilizumab has proved to be well tolerated, with a low 
frequency of side-effects [41, 47, 129]. Mitsunaga et al. 
[131] studied nine patients with advanced pancreatic 
cancer who received gemcitabine in combination with 
Tocilizumab and found no clinical benefit, but it was a 
small study and no group treated with only gemcitabine 
was included. The cell studies described for the four 
types of GI cancer (gastric cancer, biliary duct cancer, 
pancreatic cancer and colorectal cancer) provide a 
solid base for documenting the impact of IL-6 in the 
development, growth and invasion of these cancers. 
The use of IL-6 as a therapeutic target is currently being 
investigated for pancreatic cancer, but trials should be 
done for the three other cancers types, especially since 
inhibition of anti-IL-6R with Tocilizumab seems to be 
well tolerated. Another anti-IL-6 drug, Siltuximab, binds to 
circulating IL-6 preventing it from binding to its receptor, 
and has also proven to be well tolerated [28, 30, 132]. 
Although promising in theory, studies have shown that 
Siltuximab and IL-6 forms circulating complexes, which 
are unable to be cleared by the digestion of cells and renal 
clearance, resulting in a drastic increase in serum IL-6 
level when ending the treatment [30]. Another way to 
inhibit the effect of IL-6 could be to decrease the level 
of circulating IL-6. In a meta-analysis by Yu et al. [133], 
they studied the effect of omega-3 polyunsaturated fatty 
acids on patients undergoing surgery for GI cancers. The 
meta-analysis showed that serum IL-6 levels decreases 
following omega-3 fatty acids supplementation versus 
isocaloric nutrition. The supplement seemed to decrease 
the level of inflammation and increase immune function by 
modulating the cells of the immune system. This indicates 
that an attempt to target IL-6 when treating patients 
with GI cancer should incorporate different approaches, 
including both treatment with an anti-IL-6R to inhibit the 
effect of IL-6 and an attempt to lower the circulating levels 
of IL-6, for example through nutritional means. 
The idea of targeting IL-6 in cancer treatment is also 
relevant since a systemic inflammatory response is associated 
with a poorer outcome, independent of tumor stage [50]. 
IL-6 has been suggested as treatment in combination with 
immunotherapy such as immune checkpoint therapies, 
cancer peptide vaccines or immunological adjuvants, since 
IL-6 seems to downregulate the tumor-suppressing tumor 
micro-environment [37, 126] and has been tested with 
promising results in murine studies [75]. A strong systemic 
inflammatory response in cancer patients correlates with 
cancer-associated symptoms such as cachexia, anorexia, 
lowered physical function, fatigue, pain and depression. 
Although clear evidence is lacking, lowering the systemic 
immune response could thereby increase the day-to-day 
quality of life of many patients with cancer [30, 50]. 
CRP is currently used as a general biomarker of 
systemic inflammation and IL-6 induces the secretion of 
CRP from the hepatocytes [28, 92, 134]. Several of the 
studies investigated in this review assessed the correlation 
between serum IL-6 and CRP levels in cancer patients, and 
the majority found a significant correlation between IL-6 
and CRP. This has also been reported for patients with lung 
cancer [113], colorectal cancer [86, 92, 94, 95, 107], gastric 
cancer [67, 79], pancreatic cancer [48, 74, 122, 135]. 
CRP and IL-6 also correlated to cytokine intensity in 
gastric cancer [65] and certain clinical characteristics 
such as more advanced tumor stage in gastric [65, 79, 123] 
and colorectal cancer [92], shorter survival in colorectal 
[24, 94, 95], PC [135] and lung cancer [47], and cachexia 
in patients with colorectal [94], pancreatic [24, 82] 
and lung cancer [113]. CRP has been associated to 
paraneoplastic symptoms and cachexia, leading to an 
understanding of a condition with chronic elevated IL-6 
in cancer which leads to anemia, elevated CRP levels and 
a change in the gut microbiota that possibly increases the 
gut permeability further worsening the cachexia [136]. 
According to a large study by Thomsen et al. [137], a high 
serum level CRP and IL-6 was associated to a severely 
impaired health-related quality of life compared to 
patients with normal levels in 512 patients with metastatic 
colorectal cancer patients receiving first line chemotherapy 
with or without Cetuximab. 
In patients with pancreatic cancer, treatment with 
anti-IL-6R could potentially result in an amelioration 
of the severe symptoms from which many patients with 
metastatic pancreatic cancer suffer [122]. High serum 
IL-6 levels in pancreatic cancer patients are associated 
with symptoms such as anemia, metastasis, fatigue and 
most important cachexia, which is a severe complication 
for many of these patients [12, 26, 122, 138]. This is why 
a number of studies, e.g. Miura et al. [135] suggest the 
use of treatment with an anti-IL-6R antibody in treatment 
of patients with metastatic pancreatic cancer. They found 
that high IL-6 was associated with impairments in general 
activity and working ability. It has also been discussed 
whether or not the chemo-resistance of the GI cancer cells 
is dependent on IL-6 [48]. Since the literature reveals a 
poorer response to chemo-therapy when IL-6 is increased, 
evaluation of IL-6-levels might help in the development 
of personalized treatment strategies for patients with 
pancreatic cancer [26, 82]. Hence, even if targeting IL-6 
in patients with GI cancer proves not to have any anti-
tumor effect, the treatment may decrease severe cancer 
symptoms such as cachexia and fatigue, improving the 
patients’ quality-of-life [136].
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CONCLUSIONS
This systematic review found 48 publications 
investigating IL-6 as a cancer biomarker in 5316 patients 
with gastric, bile duct, gallbladder, pancreatic and 
colorectal cancer. The overall picture of IL-6 was that this 
cytokine was elevated in plasma or serum from patients 
with these types of GI cancer compared to healthy controls. 
We assessed the diagnostic value of IL-6 in the hope of 
finding methods to detect the GI cancers earlier, but IL-6 
has little value as independent single diagnostic biomarker, 
since it is not cancer specific and not sensitive enough. 
However, IL-6 might be useful as a bed-side test in general 
practice, possibly identifying patients with unspecific or 
vague symptoms of cancer. In the majority of the studies, 
serum IL-6 correlated with the clinical characteristics of 
the patients. 
The use of IL-6 as a prognostic biomarker seems 
promising for patients with gastric-, pancreatic-, and 
mayble also for bile duct cancer. The results regarding 
the prognostic use of IL-6 in colorectal cancer were 
unfortunately too equivocal to allow firm conclusions. 
In some of the studies, IL-6 did not provide additional 
information compared to serum CEA and CA 19-9.
Cancer cell studies have shown a correlation 
between IL-6 and chemo resistance and increased 
proliferation, and the use of IL-6 as a therapeutic target is 
currently being investigated. Targeting IL-6 may improve 
OS in patients with GI cancer and decrease severe cancer 
symptoms like fatigue and cachexia and improving quality 
of life in these patients.
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